Par Health Recalls Argatroban Injection Over Contaminants

Hospitals are discontinuing use of 22 lots of the blood thinner that may contain foreign particulate matter.

Updated on Oct. 21, 2026 in Stroke

Isometric editorial illustration of a sterile medical vial and empty syringe on a metal surface, illustrating a pharmaceutical product recall. — Par Health has initiated a nationwide recall of 22 lots of Argatroban Injection after discovering foreign particulate matter in the medication. AI Illustration. Upload story photo >

Live Poll

Do frequent pharmaceutical product recalls reduce your personal trust in the safety of your prescribed medication?

Par Health has initiated a nationwide recall for 22 lots of Argatroban Injection due to the presence of foreign particulate matter. This medication is commonly used in hospitals to treat or prevent blood clots in patients who cannot take heparin.

Why it matters

Particulate matter in injectable medications can lead to serious health risks, including organ damage, vein inflammation, and life-threatening pulmonary emboli. This recall ensures that potentially contaminated products are removed from hospital supply chains to protect patient safety.

The recall involves 22 specific lots of Argatroban Injection distributed nationwide over a 16-month period. As of October 20, 2026, there have been no confirmed reports of adverse events linked to the presence of foreign materials.

The players

Par Health

A pharmaceutical manufacturer responsible for the production and recall of the affected Argatroban Injection lots.

Major Pharmaceuticals

A drug manufacturer that previously issued a recall for blood-clotting medication capsules in August 2026.

The details

The recalled vials were found to contain various foreign substances, including cellulose, polystyrene, polyethylene terephthalate, stainless steel, and pieces of the container stopper. When introduced directly into the bloodstream, these particles can trigger inflammatory responses or create blockages in the pulmonary system. Hospitals and distributors have been instructed to identify and discontinue the use of all impacted inventory to prevent patient exposure.

Distribution of the affected Argatroban lots began on Dec. 30, 2024.
The distribution period for these lots ended on May 5, 2026.
Major Pharmaceuticals recalled nearly 300,000 capsules of Pradaxa in August 2026.
As of Oct. 20, 2026, no adverse health events have been linked to the Argatroban recall.

Health Landscape

This recall reflects ongoing challenges in ensuring the sterility of hospital pharmaceutical stocks, following the 2026 recall of Pradaxa capsules by Major Pharmaceuticals. These actions highlight the rigorous oversight required to maintain the safety of high-stakes anticoagulant therapies.

This recall is primarily managed at the hospital and pharmacy level, meaning you do not need to take direct action on your personal medications at home. If you are currently hospitalized or receiving intravenous anticoagulant therapy, you may ask your clinical team if your medication source has been affected.

The takeaway

Injectable medications are subject to strict quality controls to prevent the entry of hazardous foreign particles into the bloodstream. Patients concerned about the safety of inpatient treatments should always feel empowered to have a conversation with their physician or hospital care team.